GlassScriptPhysician profile
Hidenao Kimura
NPI 1770519340
$10,630.41
in general payments reported to CMS, 2019-2025
38 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,008 · 2020: $1,177 · 2021: $1,593 · 2022: $1,618 · 2023: $1,611 · 2024: $1,330 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.04 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,831.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,553.27 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $1,317.40 | 2019-2022 | |
| Pfizer INC. | $741.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $652.18 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $531.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.92 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $412.40 | 2023-2025 | |
| Abbvie INC. | $374.92 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $323.42 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $302.93 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $225.43 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $222.22 | 2021 | |
| Lundbeck LLC | $201.09 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $192.37 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hidenao Kimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.